Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
Palisade Bio, Inc. (PALI)
Price$1.69Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250,000 | $0 | — | $13,520 | $15,394 | $260,000 | $260,000 | $16,246 | $10,417 | $18,833 | $110,000 | $407,708 | $390,625 | $733,438 | — |
| Research & development | $10.2M | $9.1M | $6.9M | $6.5M | $2.4M | $3.1M | $4.1M | $4.0M | $8.1M | $13.2M | $12.6M | $8.4M | $7.3M | $6.1M | $7.4M | $9.2M | $5.3M |
| Operating expenses | $18.1M | $14.9M | $13.3M | $15.7M | $41.9M | $9.3M | $8.6M | $8.5M | $13.6M | $20.7M | $19.2M | $17.5M | $12.6M | $10.6M | $13.4M | $15.9M | $10.5M |
| Operating income | −$18.1M | −$14.9M | −$13.1M | −$15.7M | −$41.9M | −$9.3M | −$8.6M | −$8.3M | −$13.3M | −$20.6M | −$19.2M | −$17.4M | −$12.5M | −$10.2M | −$13.0M | −$15.2M | −$10.5M |
| Operating margin | — | — | −5,228.00% | — | — | −68,764.79% | −56,071.81% | −3,176.71% | −5,118.12% | −127,027.23% | −183,896.78% | −92,581.37% | −11,385.40% | −2,491.11% | −3,325.56% | −2,070.37% | — |
| EBITDA | −$18.1M | −$14.9M | −$13.1M | −$15.7M | −$41.9M | −$9.3M | −$8.5M | −$8.1M | −$13.0M | −$20.3M | −$18.8M | −$17.1M | −$12.3M | −$9.9M | −$12.8M | −$15.1M | −$10.4M |
| EBITDA margin | — | — | −5,226.40% | — | — | −68,742.60% | −55,137.29% | −3,105.25% | −5,006.88% | −124,949.74% | −180,580.47% | −90,730.20% | −11,162.92% | −2,439.32% | −3,277.68% | −2,052.54% | — |
| Net income | −$16.8M | −$14.4M | −$12.3M | −$14.3M | −$26.6M | −$10.3M | −$8.4M | −$4.9M | −$15.7M | −$21.1M | −$20.9M | −$22.6M | −$19.8M | −$10.1M | −$12.5M | −$18.4M | −$10.4M |
| Net profit margin | — | — | −4,920.00% | — | — | −76,346.15% | −54,252.64% | −1,894.08% | −6,025.38% | −129,721.85% | −200,671.03% | −120,154.75% | −18,028.97% | −2,482.54% | −3,204.74% | −2,507.00% | — |
| Basic EPSper basic share | -$0.30 | -$10.19 | -$27.01 | -$247.95 | -$2,144.25 | -$2,790.00 | -$17,100.00 | -$33,930.00 | -$108,000.00 | -$227,700.00 | -$269,100.00 | -$304,200.00 | -$315,900.00 | -$198,900.00 | -$304,200.00 | -$491,400.00 | -$351,000.00 |
| Diluted EPSper diluted share | -$0.30 | -$10.19 | -$27.01 | -$247.95 | -$2,546.10 | -$2,790.00 | -$17,100.00 | -$33,930.00 | -$108,000.00 | -$227,700.00 | -$269,100.00 | -$304,200.00 | -$315,900.00 | -$198,900.00 | -$304,200.00 | -$491,400.00 | -$351,000.00 |
Owners
Reported shareholders
7.53%of listed shares
Soleus Capital Management, L.P.13.06M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Soleus Capital Management, L.P. | 7.53%13.06M shares |
B Group, Inc. | 6.58%11.41M shares |
AMERIPRISE FINANCIAL INC | 6.38%11.08M shares |
Jupiter Topco LLC | 6.16%10.69M shares |
BlackRock, Inc. | 6.01%10.44M shares |
Octagon Capital Advisors LP | 5.92%10.28M shares |
PERCEPTIVE ADVISORS LLC | 4.85%8.43M shares |
RA CAPITAL MANAGEMENT, L.P. | 4.10%7.12M shares |
FRANKLIN RESOURCES INC | 3.33%5.79M shares |
Point72 Asset Management, L.P. | 3.03%5.25M shares |
Boxer Capital Management, LLC | 2.76%4.8M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.59%4.5M shares |
Eversept Partners, LP | 2.41%4.18M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.17%3.76M shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.13%3.7M shares |
GOLDMAN SACHS GROUP INC | 2.06%3.58M shares |
FEDERATED HERMES, INC. | 1.81%3.14M shares |
Squadron Capital Management LLC | 1.73%3M shares |
Propel Bio Management, LLC | 1.49%2.58M shares |
Vestal Point Capital, LP | 1.44%2.5M shares |
Percentages use 173.6M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026Form 4 | Jones Mitchell LawrenceChief Medical Officer | SellCommon Stock | 2.0K | $1.75 | $3.5K | 13.3K |
| Feb 12, 2026Form 4 | Finley John DavidCEO, CFO | SellCommon Stock | 3.9K | $1.75 | $6.8K | 27.4K |
| Jan 16, 2026Form 4 | Williams Donald AllenDirector | BuyCommon Stock | 5.0K | $1.67 | $8.3K | 10.7K |
| Jan 9, 2026Form 4 | Williams Donald AllenDirector | BuyCommon Stock | 5.0K | $1.88 | $9.4K | 5.7K |